
|Videos|July 7, 2016
The Impact of PCSK9 Inhibitors on Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.
Advertisement
Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Early Oral Antiviral Use Associated With Lower Risk of Post–COVID-19 Condition, Study Finds
2
Retatrutide Delivers Bariatric-Level Weight Loss in Pivotal Phase 3 TRIUMPH-1 Trial
3
From GLP-1s to Vaccines, APhA 2026 Showcased the Modern Clinical Pharmacist
4
Oral GLP-1 Orforglipron Is Approved for Obesity
5





































































































































